Aspira Women`s Health Inc Stock Price, News & Analysis

Aspira Women’s Health Inc. (Nasdaq: AWH) announced it will release its third-quarter financial results for the period ending September 30, 2022, on November 10, 2022. The company will hold a conference call at 8:30 AM ET that day to discuss the results and provide a corporate update. Aspira focuses on women's health through innovative testing options and bio-analytical solutions, aiming to improve gynecologic health outcomes. This includes addressing disparities in ovarian cancer risk assessment and developing solutions for pelvic diseases.

Aspira Women’s Health has announced participation in the MicroCap Rodeo Presents Windy City Roundup 2022 conference in Chicago on October 12-13, 2022. The company will engage in one-on-one meetings and presentations to showcase its innovative women’s health solutions aimed at improving gynecologic health outcomes. Aspira focuses on addressing ovarian cancer risks and developing diagnostics for pelvic diseases. The conference aims to enhance investor relations and can be accessed via webcast. More details are available on their Investor Relations website.

Aspira Women’s Health has launched a collaboration with BioReference to co-market and distribute Ova1Plus, a blood test aimed at assessing the risk of ovarian malignancy in women with adnexal masses. This partnership will expand access to Ova1Plus across the U.S. healthcare system. Both companies aim to enhance care and market presence, with expectations of increased revenue and improved provider adoption. The alliance marks a significant step for Aspira in its mission to improve women’s health diagnostics.

Aspira Women’s Health Inc. announced a study published in the International Journal of Environmental Research and Public Health confirming the effectiveness of its ovarian cancer test, MIA2G (OVERA), in a non-White population. The research demonstrated OVERA’s sensitivity in detecting early-stage ovarian cancer at 92.4%, outperforming CA-125 at 74.3%. This study emphasizes the potential of OVERA as a preferred diagnostic tool for early cancer detection, especially for Filipino women, potentially influencing clinical assessment standards.

Aspira Women’s Health Inc. (Nasdaq: AWH) has announced the pricing of a public offering of 12,000,000 shares of common stock and 12,000,000 accompanying warrants at a combined price of $0.75 per share. The company expects to raise approximately $9.0 million from the offering, which is set to close on August 25, 2022. Proceeds will be utilized for working capital, product expansion, and strategic partnerships. The offering is registered under SEC File No. 333-252267.

Aspira Women’s Health Inc. (Nasdaq: AWH) announced an underwritten public offering of its common stock and warrants. The offering is subject to market conditions, with no assurance on completion timing or terms. Proceeds will be used for working capital, corporate purposes, product portfolio expansion, and potential strategic investments.

William Blair & Company acts as the sole book-running manager. Details regarding the offering will be filed with the SEC and are available on their website.

Aspira Women’s Health will host a KOL webinar on women's health and ovarian cancer risk assessments on August 24, 2022, at 12:00 PM ET. Executives will present alongside KOLs discussing the OVA1Plus and OVAWatch tests. The OVA1Plus test aids in assessing ovarian cancer risk, while OVAWatch will target women with pelvic masses not scheduled for surgery. This event aims to enhance awareness and understanding of innovative diagnostic tools in women's health.

Aspira Women’s Health Inc. (AWH) reported a 17% increase in product revenue to $2.0 million for Q2 2022, with OVA1plus test volume rising 19% to 5,411 units. The company entered a research agreement with Harvard’s Dana-Farber Cancer Institute and others to develop a diagnostic test for endometriosis. Additionally, cash utilization was reduced by $3.9 million from the prior quarter. Despite these gains, gross profit margin for OVA1plus decreased to 49% from 52% year-over-year. A conference call is scheduled for today at 8:30 a.m. ET.

Aspira Women’s Health announced the upcoming release of its financial results for Q2 2022 on August 10, 2022, before market open. The company will also host a conference call at 8:30 am ET to discuss these results and provide a corporate update. Aspira focuses on innovative testing solutions and bio-analytical products aimed at improving gynecologic health outcomes, specifically in ovarian cancer risk assessment. Their OVA1plus combines FDA-cleared products to assess ovarian malignancy risk. More details are available on their website.